Metabolomic Analysis of Atherothrombosis

Although great advances have been made in diagnosing acute coronary syndrome (ACS), all of the current ACS biomarkers measure the result, myocardial necrosis, and not the cause and therapeutic target -atherothrombosis. The goal of this project is to develop a biomarker which differentiates atherothrombotic from non-atherothrombotic MI in patients with Type2 Diabetes (T2D). Such an approach will not only improve diagnostic accuracy but could also potentially identify events at the start of coronary thrombosis, prior to “inevitable” myocardial necrosis, allowing for more prompt and targeted interventions. Using both targeted and unbiased metabolomic approaches, we are searcing for the specific biomarkers of atherothrombosis. Our central hypothesis is atherothrombotic events are associated with increased production of metabolites derived from oxidized lipids in the culprit lesion or generated by the atherothrombotic event itself and that measurement of these metabolites will allow for early and accurate diagnosis of atherothrombotic MI is T2D patients.

Principal Investigator

Andrew DeFilippis, M.D.

Andrew DeFilippis, M.D.

Assistant Professor of Medicine
Director, Advanced Cardiac Support Center
E-mail Andrew DeFilippis

MD, Georgetown University School of Medicine, Washington, DC.
Residency, Internal Medicine, Emory University School of Medicine
Fellowship, Cardiology, Johns Hopkins University School of Medicine.

Related links:
Video: Myocardial Infarctions: Are They All The Same?

The Association of Framingham and Reynolds Risk Scores With Incidence and Progression of Coronary Artery Calcification in MESA (Multi-Ethnic Study of Atherosclerosis)

Advanced chronic obstructive pulmonary disease is associated with high levels of high-density lipoprotein cholesterol